These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28977680)

  • 41. Questiomycin A stimulates sorafenib-induced cell death via suppression of glucose-regulated protein 78.
    Machihara K; Tanaka H; Hayashi Y; Murakami I; Namba T
    Biochem Biophys Res Commun; 2017 Oct; 492(1):33-40. PubMed ID: 28811106
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
    Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
    Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
    Leconte M; Santulli P; Chouzenoux S; Marcellin L; Cerles O; Chapron C; Dousset B; Batteux F
    Reprod Sci; 2015 Sep; 22(9):1171-80. PubMed ID: 26169036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sorafenib prolongs liver regeneration after hepatic resection in rats.
    Mollbrink A; Augsten M; Hultcrantz R; Eriksson LC; Stål P
    J Surg Res; 2013 Oct; 184(2):847-54. PubMed ID: 23726434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
    Houessinon A; François C; Sauzay C; Louandre C; Mongelard G; Godin C; Bodeau S; Takahashi S; Saidak Z; Gutierrez L; Régimbeau JM; Barget N; Barbare JC; Ganne N; Chauffert B; Coriat R; Galmiche A
    Mol Cancer; 2016 May; 15(1):38. PubMed ID: 27184800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The protective effect of losartan against sorafenib induced cardiotoxicity: Ex-vivo isolated heart and metabolites profiling studies in rat.
    Abdelgalil AA; Mohamed OY; Ahamad SR; Al-Jenoobi FI
    Eur J Pharmacol; 2020 Sep; 882():173229. PubMed ID: 32505666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.
    Rudalska R; Dauch D; Longerich T; McJunkin K; Wuestefeld T; Kang TW; Hohmeyer A; Pesic M; Leibold J; von Thun A; Schirmacher P; Zuber J; Weiss KH; Powers S; Malek NP; Eilers M; Sipos B; Lowe SW; Geffers R; Laufer S; Zender L
    Nat Med; 2014 Oct; 20(10):1138-46. PubMed ID: 25216638
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.
    Carra E; Barbieri F; Marubbi D; Pattarozzi A; Favoni RE; Florio T; Daga A
    Cell Cycle; 2013 Feb; 12(3):491-500. PubMed ID: 23324350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.
    Bae S; D'Cunha R; Shao J; An G
    Eur J Pharm Sci; 2018 May; 117():27-34. PubMed ID: 29425861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
    Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
    Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
    Coriat R; Nicco C; Chéreau C; Mir O; Alexandre J; Ropert S; Weill B; Chaussade S; Goldwasser F; Batteux F
    Mol Cancer Ther; 2012 Oct; 11(10):2284-93. PubMed ID: 22902857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.
    Mazzoccoli G; Miele L; Oben J; Grieco A; Vinciguerra M
    Curr Drug Targets; 2016; 17(7):783-99. PubMed ID: 26648069
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.
    Martin del Campo SE; Levine KM; Mundy-Bosse BL; Grignol VP; Fairchild ET; Campbell AR; Trikha P; Mace TA; Paul BK; Jaime-Ramirez AC; Markowitz J; Kondadasula SV; Guenterberg KD; McClory S; Karpa VI; Pan X; Olencki TE; Monk JP; Mortazavi A; Tridandapani S; Lesinski GB; Byrd JC; Caligiuri MA; Shah MH; Carson WE
    J Immunol; 2015 Sep; 195(5):1995-2005. PubMed ID: 26238487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
    Zheng M; Xu H; Liao XH; Chen CP; Zhang AL; Lu W; Wang L; Yang D; Wang J; Liu H; Zhou XZ; Lu KP
    Oncotarget; 2017 May; 8(18):29771-29784. PubMed ID: 28404959
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
    Karashima T; Komatsu T; Niimura M; Kawada C; Kamada M; Inoue K; Udaka K; Kuroda N; Shuin T
    Int J Urol; 2014 Jul; 21(7):702-6. PubMed ID: 24571181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
    Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
    Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
    Yi P; Higa A; Taouji S; Bexiga MG; Marza E; Arma D; Castain C; Le Bail B; Simpson JC; Rosenbaum J; Balabaud C; Bioulac-Sage P; Blanc JF; Chevet E
    Mol Cancer Ther; 2012 Dec; 11(12):2610-20. PubMed ID: 23041544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf.
    Chen KF; Tai WT; Huang JW; Hsu CY; Chen WL; Cheng AL; Chen PJ; Shiau CW
    Eur J Med Chem; 2011 Jul; 46(7):2845-51. PubMed ID: 21531053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
    Elsner A; Lange F; Fitzner B; Heuschkel M; Krause BJ; Jaster R
    World J Gastroenterol; 2014 Jun; 20(24):7914-25. PubMed ID: 24976727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.